Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 13.75p 0 08:00:00
Bid Price Offer Price High Price Low Price Open Price
13.00p 14.50p 13.75p 13.75p 13.75p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 5.03 1.63 1.93 7.1 15.0

Synairgen (SNG) Latest News

More Synairgen News
Synairgen Takeover Rumours

Synairgen (SNG) Share Charts

1 Year Synairgen Chart

1 Year Synairgen Chart

1 Month Synairgen Chart

1 Month Synairgen Chart

Intraday Synairgen Chart

Intraday Synairgen Chart

Synairgen (SNG) Discussions and Chat

Synairgen Forums and Chat

Date Time Title Posts
06/12/201808:29Synairgen - a cure for Asthma?935
19/10/201007:22Synairgen - Blockbusting potential50
17/3/201018:34Canadian Superior Energy: No.American Gas&Oil8

Add a New Thread

Synairgen (SNG) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Synairgen trades in real-time

Synairgen (SNG) Top Chat Posts

Synairgen Daily Update: Synairgen Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SNG. The last closing price for Synairgen was 13.75p.
Synairgen Plc has a 4 week average price of 13.50p and a 12 week average price of 13.50p.
The 1 year high share price is 26.50p while the 1 year low share price is currently 10.88p.
There are currently 109,433,442 shares in issue and the average daily traded volume is 14,256 shares. The market capitalisation of Synairgen Plc is £15,047,098.28.
richthenewbie: Leonard Licht still accumulating here (may have been during placing). His stake up to nearly 10% now:
pdt: gab147 - hTTps:// scroll down the page to announcements and it is contained in the "Trading Halt" release.
gab147: I agree with you Nobby - the share price should be double at least if it truly represents the potential future income from these drugs.
ohisay: Much as expected and I'd be surprised if the biomarker results weren't just as good as in previous years . This was from last years results (primarily commenting on the AZ Inexas trial ). We are however very encouraged to observe that the lungs' antiviral defences had been switched on - as demonstrated by significant changes in an accepted biomarker of the interferon pathway. Indeed this is the third trial where this activation has been shown. Finncap had an extra 10p to add to their initial 35p target for a confirmed safety/biomarker COPD result so still all to play for here.
ohisay: Indeed .COPD safety study due first I think. Worth recalling the House broker view ... Broker FinnCap reckons the stock is worth 35p based on a discounted cash flow (DCF) valuation that that puts 17p and 18p a share price tags on, respectively, SNG001 and LOXL2. This DCF valuation will rise to £41mln, or 45p a share following the successful completion of a pilot safety study of SNG001
rosejs2: Nobby... You are not talking to yourself.. I agree with all of your points.. SNG is a unique share... the 17% of Pharmaxis LOXL2 offers huge opportunity .. with an expected upfront payment to Pharmaxis of up to $50m (if the Phase 1 trials prove successful) and further signifcant stage payments on its journey to commercialisation. The Income coffers of SNG COULD soon be flush with substantial additional funds.. With the commencement of Phase 2 Trials on SNGs own Interferon B now underway... with initial results in Q2 2018...There cannot be a share as unique as SNG to hold.. No debt, enough cash rerserves topped up by the recent £5m payment from Pharmaxis achieving full control of the LOXL2 programme .. It is a share to watch, hold and wait for information that can and might lead to many multiples of its current share price.. IMHO.
rosejs2: SNG appears to be an invisible gem to the majority of Investors.. We have a unique British Company based in Southampton General Hospital using its differentiating human biology BioBank platform and world-renowned international academic Key Opinion Leader network to discover and develop novel therapies for respiratory disease.Prof Stephen Holgate, Medical Research Council Clinical Professor of Immunopharmacology at the University of Southampton is a Non Exec Director of SN SNG will very soon have £5m from Pharmaxis, plus my guess is approx £2.0 million in its cash reserves.. and importantly NO DEBT... Approx 64% of the shares are held by 5 shareholders with Woodford Investment Managers holding over 23% of the SNG share capital..and approx 91 Million shares in existance.. With a dynamic management led by CEO Richard Marsden, who I calculate pulled off a unique and lucrative deal of SNG investing my guess is £3m in LOXL2 and 2 years later has converted this investment into a £5m Paycheck for shareholders and critcally important a 17% stake in the COMPLETE Pharmaxis LOXL Programme... Phase 1 Trials by Pharmaxis in the LOXL Programme are commencing with the following comment by its CEO “Ongoing discussions with multinational Pharma companies suggest that there is a significant opportunity for an oral once a day LOXL2 inhibitor in a number of fibrotic diseases with a high unmet need.  With COPD news by SNG expected sometime after Q1 2018 and regular updates by Pharmaxis on its LOXL Programme during Q1 and Q2 2018... The potential risk reward for Synairgen shareholders does offer a very signifcant reward opportunity.. for those willing to complete the journey to see both these key Programmes end points.. A very successful and prosperous New Year to current and future SNG Investors.
rosejs2: ohisay ... I do agree with your sentiments.. Here we have a company with NO debt, £5m to come from Pharmaxis, 17% of future revenues from LOXL2 Developments (these could be huge if the Phase 1 trials meet expectations and the right partners found)... Approx £2m in current cash... Alongside progression of SNG001 into COPD, What is there not to like.. If you look at the Major shareholders 5 of which including Woodford Investment Management own approx 64% of the issued equity...only 91.36 million shares... Both areas of development LOXL2 and COPD are if successfull worth Billions to major Pharma Partners... whilst the 'IF' is speculative.. the quality of both Management and Scientific Expertise in both Pharmaxis and SNG is second to none.. Why is the share price falling ? my view for what it is worth is that SNG shares are quite illiquid small sales or purchases can move the price one way or the other .. and currently some small sells are driving the price down.. It may on the other hand be a tree shaking exercise by the market makers who require stock to meet their obligations.. and hitting individual stop losses may be the only way to obtain stock... but that is just my speculation.. 2018 will be a very exciting year for SNG for both LOXL2 and progress on COPD ... If SNG management can supply regular updates on progress, the market should become more aware of the real potential of SNG and its revenue streams. The market should then respond positively in raising SNG shares substantially above its current lowly Price..
rosejs2: Has it occured to others why Pharmaxis did not bid for SNG as a means of achieving 100% ownership of the LOXL2 Programme ? or was there an attempt to do so before signing the latest agreement with SNG to share revenues... Might the large shareholders have been (quite rightly ) demanding a price substantially in excess of the current share price ? Might Pharmaxis be a future bidder of SNG if all goes well with its Phase 1 / Partnership agreements... And be able to add SNG's COPD potential blockbuster to its portfolio ?
wookie77: Thanks Ohisay........If SNG share price can get above the 40p neck line then we really are off to the races IMO.
Synairgen share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181215 07:31:13